Non–Vitamin K Antagonist Oral Anticoagulants effective in Stroke treatment
Stroke management is very crucial as as neurons do not survive longer in case of hypoxia. Current guidelines recommend against use of intravenous alteplase in patients with acute ischemic stroke who are taking non–vitamin K antagonist oral anticoagulants (NOACs).A recent Results published in JAMA Network concluded that Among patients with acute ischemic stroke treated with...
Stroke management is very crucial as as neurons do not survive longer in case of hypoxia. Current guidelines recommend against use of intravenous alteplase in patients with acute ischemic stroke who are taking non–vitamin K antagonist oral anticoagulants (NOACs).
A recent Results published in JAMA Network concluded that Among patients with acute ischemic stroke treated with intravenous alteplase, use of non–vitamin K antagonist oral anticoagulants within the preceding 7 days was not associated with a significantly increased risk of intracranial hemorrhage.
Study evaluated the safety and functional outcomes of intravenous alteplase among patients who were taking non–vitamin K antagonist oral anticoagulants prior to stroke and compared the outcomes with patients who were not taking long-term anticoagulants.
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd